Clinical Trials Logo

Filter by:
NCT ID: NCT02015520 Completed - Clinical trials for Rheumatoid Arthritis

Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis

Start date: June 2012
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to identify an appropriate dose of study medication.

NCT ID: NCT02014753 Completed - Clinical trials for Coronary Artery Disease

Multicenter Comparison of Early and Late Vascular Responses to Everolimus-eluting Cobalt-CHromium Stent and Platelet AggregatioN studIeS for TreatMent of Acute Myocardial InfarctionTreatment of ST-elevation Acute Myocardial Infarction

MECHANISM-AMI
Start date: April 30, 2014
Phase:
Study type: Observational

To treat patients with acute myocardial infarction, primary percutaneous coronary intervention (PCI) will be performed with the use of an everolimus-eluting cobalt- chromium stent (everolimus-eluting stent: EES, Xience Prime, Xpedition), which is the current standard drug-eluting stent (DES). Vascular responses at the site of stent placement will be evaluated by optical coherence tomography (OCT) at 2 weeks or 3 months and at 12 months after stent placement, along with observation of changes over time in the target vessel. The relationships between OCT findings and the time course of platelet aggregation and between OCT findings and the occurrence of major cardio- cerebrovascular events will also be elucidated.

NCT ID: NCT02014129 Completed - Lymphoma Clinical Trials

A Study of LY2835219 in Japanese Participants With Advanced Cancer

Start date: December 18, 2013
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate safety and side effects of LY2835219 in Japanese participants with advanced cancer.

NCT ID: NCT02014051 Completed - Clinical trials for Myelodysplastic Syndrome

Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)

Start date: March 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate tolerability when SyB C-1101 is orally administered twice daily for 14 consecutive days to the patients with recurrent/relapsed or refractory myelodysplastic syndrome, to determine the dose-limiting toxicity and maximum tolerated dose, and to estimate the recommended dose for phase II studies. Pharmacokinetics and antitumor effects will also be investigated.

NCT ID: NCT02013362 Completed - Clinical trials for Peripheral T-cell Lymphoma

Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Start date: March 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I portion: To evaluate the safety and tolerability of pralatrexate with concurrent vitamin B12 and folic acid supplementation in Japanese patients with relapsed or refractory PTCL and to determine the recommended dosage. Also, to evaluate pharmacokinetics. Phase II portion: To evaluate the efficacy, safety, and pharmacokinetics of the recommended dosage regimen determined in the phase I portion. The primary efficacy endpoint shall be objective response rate (ORR).

NCT ID: NCT02012543 Completed - Constipation Clinical Trials

Effect of Agar Administration on Defecation and Fecal Condition in Chronic Constipated Patients

Start date: November 2013
Phase: N/A
Study type: Interventional

The administration of agar jelly may increase the number of defecation and the volume of feces, and then may improve fecal condition in chronic constipated patients.

NCT ID: NCT02011113 Completed - Multiple Myeloma Clinical Trials

Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma

Start date: December 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of pomalidomide in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma.

NCT ID: NCT02008357 Completed - Cognition Disorders Clinical Trials

Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss

A4
Start date: February 28, 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer Disease [AD]).

NCT ID: NCT02008227 Completed - Clinical trials for Non-Squamous Non-Small Cell Lung Cancer

A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy

OAK
Start date: March 11, 2014
Phase: Phase 3
Study type: Interventional

This global, multicenter, open-label, randomized, controlled study evaluated the efficacy and safety of atezolizumab (an anti-programmed death−ligand 1 [anti-PD-L1] antibody)compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure with platinum-containing chemotherapy. Participants were randomized 1:1 to receive either docetaxel or atezolizumab. Treatment may continue as long as participants experienced clinical benefit as assessed by the investigator, i.e., in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.

NCT ID: NCT02007655 Completed - Clinical trials for NonValvular Atrial Fibrillation

Eliquis Safety Surveillance in Japanese Patients With NonValvular Atrial Fibrillation

Start date: September 1, 2013
Phase:
Study type: Observational

The primary objectives of this study are: - To estimate the incidence rate of unexpected adverse events - To characterize the bleeding events and assess risk factors of bleeding - To identify ancillary baseline variables that may also be associated with adverse outcomes